Please login to the form below

Not currently logged in
Email:
Password:

BMS lobbying spend reaches USD 2.8m

Bristol-Myers Squibb spent over USD 2.8m in H1 2007 to lobby the US Federal government over patent protection

US-headquartered pharmaceutical company Bristol-Myers Squibb (BMS) spent over USD 2.8m in H1 2007 to lobby the US Federal government over patent protection.

The company continues to lobby for patent protection for the pharmaceutical industry, free trade agreements and more funding for the FDA, according to a form posted online by the Senate's public records office on 10 October 2007.

In early September 2007, the House approved a patent reform bill intended to reduce patent litigation, improve patent quality, increase information available to patent examiners and establish a post-approval patent re-evaluation process.

While technology and financial services firms supported the legislation, pharmaceutical and biotechnology companies claim it will weaken patent protection by reducing infringement penalties and permitting post-approval challenges to patents.

The Senate is also considering similar legislation.

BMS has also been lobbying the Agriculture and Commerce departments and the US Trade Representative's office.

GlaxoSmithKline (GSK) has already instigated a lawsuit which seeks an injunction against the US Patent and Trademark Office (PTO) to stop them from bringing into effect new rules as of 1 November 2007. GSK says the new law will stifle innovation.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics